Concepedia

Publication | Closed Access

A phase I trial of solubilized DR2:MBP <sup>84-102</sup> (AG284) in multiple sclerosis

DOI

68

Citations

19

References

2000

Year

Donald E. Goodkin, Megan Shulman, J L Winkelhake, Emmanuelle Waubant, P.-B. Andersson, Thomas Stewart, Sarah J. Nelson, Nancy J. Fischbein, Patricia K. Coyle, Elliot M. Frohman,
Neurology

Abstract

AG284 as administered during this study was safe and well tolerated. Further studies are warranted to determine the biologic activity and clinical efficacy of this potential treatment for MS.

References

YearCitations

Page 1